Can Illumina Hold Its Price as EPS Improves but Cash Flow Drops?

Illumina just gave investors two opposite takes on the same quarter

Illumina lifted guidance, but one key cash flow figure fell, so the stock now has to back up the better headline. Management raised its full-year revenue view to $4.60 billion to $4.64 billion, and the company also highlighted demand for NovaSeq X remains high. At the same time, investors are left watching whether reported growth is turning into stronger cash generation.

The bullish read is straightforward. Illumina posted Q2 revenue of $1.16 billion, up 9.5% from Q2 2025, and delivered GAAP diluted EPS of $1.35. Combined with a higher year outlook, that supports the case that demand is real and the ecosystem is still holding value.

The bearish read is just as simple. Strong revenue and EPS do not matter as much if cash collection, working capital, or timing issues keep money out of the bank. That tension is why the next few quarters matter more than the excitement around the guidance raise.

The earnings-versus-cash tension is the real test

Profit can improve while cash lags if receivables rise, inventory builds, or instrument shipments arrive before the repeat consumable revenue shows up. That is why the latest quarter matters beyond its headline growth: investors now need proof that better earnings are converting into better cash.

Fiscal 2025 shows why the debate exists

The cleanest backdrop is last year. Illumina ended fiscal 2025 with revenue of $4.34 billion, flat compared to 2024, while still posting a non-GAAP operating margin of 23.1% and non-GAAP diluted EPS of $4.84. That combination helps explain why investors should not assume better EPS automatically means a stronger operating payoff.

What bulls and bears are actually debating

Bulls are arguing that Illumina is no longer stuck in a flat-growth phase. The raised revenue outlook, stronger Q2 growth, and claims that demand for NovaSeq X remains high all point to a platform that customers still want. If that hardware is staying in labs, consumables and workflows should eventually follow.

Bears are focusing on the cash side of the story. Even with better guidance, investors still need evidence that the higher demand is producing cleaner cash conversion rather than just a better-looking income statement.

For ILMN shares to hold their price, cash flow needs to catch up

The next move depends less on another neat quarter and more on whether Illumina can show that this is really a repeat-buy business. Management is right that demand for NovaSeq X remains high, and that matters. But the shares are more likely to hold up if that demand shows up consistently in cash, not only in guidance and EPS.

What investors should watch next

• Cash follows demand. The next few reports need to show that stronger sales are not getting absorbed by slower collections or heavier working capital.
• Demand stays visible. Another quarter of solid revenue and earnings would help, but it matters most if it lines up with better cash generation.
• The platform story converts into recurring spend. If lab usage keeps expanding, investors should see that reflected in more predictable recurring revenue and cleaner cash follow-through.